OMERACT: An international initiative to improve outcome measurement in rheumatology

Abstract

OMERACT is the acronym for an international, informally organized network initiated in 1992 aimed at improving outcome measurement in rheumatology. Chaired by an executive committee, it organizes consensus conferences in a 2-yearly cycle that circles the globe. Data driven recommendations are prepared and updated by expert working groups. Recommendations include core sets of measures for most of the major rheumatologic conditions. Since 2002 patients have been actively engaged in the process.

Statistics In Brief: Minimum Clinically Important Difference—Availability of Reliable Estimates

“…Cook's interpretation of this seminal definition establishes two essential characteristics: (1) a minimal amount of change perceived by the patient; and (2) a change sufficiently relevant to determine a modification in patient management. The alternative term, minimal clinically important improvement (MCII) is defined as the ''smallest change in measurement that signifies an important improvement'' [16], and has encountered more support than the MCID in musculoskeletal research, especially in rheumatology [31,32]. In the accompanying tables (Tables 1-8), we refer to their results as MCID or MCII, but acknowledge it may not be consistent among them.…”

Botulinum toxin type A versus botulinum toxin type B for cervical dystonia

“…Finally, in conducting this systematic review we were faced with the fact that there is no defined Core Outcome Set in cervical dystonia research, as there is in other areas (Tugwell 2007). The definition of a set of core outcome measures to be included in future research, via wellestablished methodology to determine the inclusion of patient-reported outcomes (Macefield 2014) …”

Improving the relevance and consistency of outcomes in comparative effectiveness research

“…Since then, particularly notable work relating to outcome standardization has been undertaken by the OMERACT (Outcome Measures in Rheumatology) initiative [22], which has advocated the use of COS, designed using consensus techniques, in clinical trials in rheumatology since their first conference in 1992 [23]. OMERACT has served a critical role in the development and validation of clinical and radiographic outcome measures in rheumatoid arthritis (RA), osteoarthritis, psoriatic arthritis, fibromyalgia and other future science group Perspective Tunis, Clarke, Gorst et al…”